Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ)
→
LabCorp

Asset Acquisition · Cash · LH · announced Mar 28, 2024

View in network
  1. Announced

    Mar 28, 2024

  2. Closed

    Sep 16, 2024

Economics

Cash

Approximately $237.5M in cash per OPKO 8-K Item 1.01 (agreement) and Item 2.01 (completion), subject to adjustments set forth in the Asset Purchase Agreement dated Mar 27, 2024; no earnout disclosed. Select-asset purchase, not a whole-company acquisition: clinical diagnostics and reproductive and women's health testing outside New York and New Jersey; oncology, urology and all New York and New Jersey operations excluded. Acquired assets generated approximately $100M annual revenue per the Labcorp release.

Target

BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ)

Diagnostics · Diagnostic / genomic

HQ Elmwood Park, NJ

BioReference Health laboratory testing business focused on clinical diagnostics and reproductive and women's health in the US outside New York and New Jersey, including patient service centers, customer contracts and operating assets (approximately $100M annual revenue); divested by OPKO Health subsidiary BioReference Health to Labcorp, which excluded oncology, urology and NY/NJ operations

  • SEC EDGAR - OPKO Health 8-K Item 1.01 (Mar 28, 2024; Asset Purchase Agreement dated Mar 27, 2024) https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/opk20240311_8k.htm
  • SEC EDGAR - OPKO Health 8-K Item 2.01 (Sep 16, 2024; completed) https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/opk20240903_8k.htm
  • Labcorp press release via PR Newswire (Mar 28, 2024; About BioReference Health: "Headquartered in Elmwood Park, New Jersey") https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-acquisition-select-assets-bioreference-healths

Acquirer

LabCorp (LH)

Diagnostics

HQ Burlington, NC

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Labcorp acquires BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health outside New York and New Jersey, including patient service centers, customer contracts and operating assets, to enhance its laboratory services network and expand access to its clinical laboratory services

Evidence ladder

Dual-source corroborationValue disclosed
  1. Primary (regulatory / filing)

    SEC EDGAR 8-K Item 1.01 (OPKO Health, Mar 28, 2024) https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/opk20240311_8k.htm

    Open source
  2. Primary (regulatory / filing)

    SEC EDGAR 8-K Item 2.01 (OPKO Health, Sep 16, 2024 — completed) https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/opk20240903_8k.htm

    Open source
  3. Secondary (press / IR)

    Labcorp press release (Mar 28, 2024) https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-acquisition-select-assets-bioreference-healths

    Open source
  4. Secondary (press / IR)

    Labcorp press release (Sep 16, 2024 — completed) https://ir.labcorp.com/news-releases/news-release-details/labcorp-completes-acquisition-select-assets-bioreference-healths

    Open source
  5. Tertiary (trade / analyst)

    MedTech Dive coverage (Mar 29, 2024) https://www.medtechdive.com/news/labcorp-buys-bioreference-reproductive-women-health-assets/711713/

    Open source

Limitations

  • Approximately $237.5M in cash per OPKO 8-K Item 1.01 (agreement) and Item 2.01 (completion), subject to adjustments set forth in the Asset Purchase Agreement dated Mar 27, 2024; no earnout disclosed. Select-asset purchase, not a whole-company acquisition: clinical diagnostics and reproductive and women's health testing outside New York and New Jersey; oncology, urology and all New York and New Jersey operations excluded. Acquired assets generated approximately $100M annual revenue per the Labcorp release.

Valuation peers · Diagnostics

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Why included
BioReference Health (clinical, women's health, urology and 4Kscore assets)LabCorpOct 15, 2026same evidence class · same acquirer

Same-sector adjacency — not valuation peers

These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.

Vs this deal
Invitae Reproductive HealthNateraJan 22, 2024

Other verified deals by LabCorp

Acquirer program history not already listed as a valuation peer or adjacency row.

Sector
Ovia HealthLabCorpAug 12, 2021UndisclosedMaternal Health
SequenomLabCorpJul 27, 2016Diagnostics

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ) (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 5 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.